Literature DB >> 17073890

Quality of requests for serum digoxin concentrations: experience from an Australian regional health service.

Chris Ellington1, Nick Grgurinovich, John O Miners, Arduino A Mangoni.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Therapeutic drug monitoring of serum digoxin concentrations (SDC) is considered useful in enhancing the therapeutic benefits of digoxin and minimizing the incidence of adverse drug reactions. * The quality of requests for SDC has been reported to be generally unsatisfactory. However, studies have focused on few information parameters. * A better knowledge of these issues might be useful to target appropriate areas of weakness within heathcare systems. WHAT THIS STUDY ADDS: * The poor quality of the information in SDC requests involves a wide range of codes from the contact details of the requester to the time interval between the last dose of digoxin and blood sampling. * Misuse of the therapeutic drug monitoring service is common across different specialties and healthcare settings. AIMS: To assess the quality of the information provided with serum digoxin concentration (SDC) requests received by a therapeutic drug monitoring service in a regional health service.
METHODS: We conducted a retrospective audit of a consecutive series of 685 SDC requests during a 7-month period. Information regarding (i) contact details, (ii) reasons for request, (iii) dose, (iv) route of administration, (v) concurrent therapy, (vi) treatment duration and (vii) time interval between the last dose and sampling was reviewed and coded as appropriate or inappropriate/missing. Data were analysed according to the origin of request, i.e. from different specialties/wards (emergency department and critical care, cardiology and coronary care unit, medicine and aged care, surgery, and general/private practice) and healthcare settings (teaching hospital, geriatric hospital and general/private practice).
RESULTS: The quality of SDC requests was generally poor across different specialties and healthcare settings. The information provided for the coded parameters was appropriate only in 19.1% (i), 6.4% (ii), 54.7% (iii), 45.8% (iv), 12.8% (v), 32.9% (vi) and 47.1% (vii) of cases. No SDC request was complete in all the information codes. SDC requests from general/private practice lacked more often details regarding the dose (information provided in 46.7% of requests, P = 0.007 vs. other specialties; P = 0.02 vs. other settings) and the route of administration (20.0%, P < 0.001 vs. other specialties and vs. other settings). SDC requests from the emergency department and critical care unit lacked more often details regarding the treatment duration (22.6%, P < 0.001 vs. other specialties) and the time interval between the last dose and blood sampling (40.1%, P = 0.01 vs. other specialties).
CONCLUSIONS: The quality of the information in SDC requests is poor across different specialties and healthcare settings. Educational strategies to ensure the appropriate use of this service are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073890      PMCID: PMC2000750          DOI: 10.1111/j.1365-2125.2006.02802.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  2001       Impact factor: 4.335

2.  A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring.

Authors:  Philip Chen; Milenko J Tanasijevic; Ronald A Schoenenberger; Julie Fiskio; Gilad J Kuperman; David W Bates
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

Review 3.  Digoxin in the management of cardiovascular disorders.

Authors:  Mihai Gheorghiade; Kirkwood F Adams; Wilson S Colucci
Journal:  Circulation       Date:  2004-06-22       Impact factor: 29.690

4.  Strategies for physician education in therapeutic drug monitoring.

Authors:  D W Bates; S J Soldin; P M Rainey; J N Micelli
Journal:  Clin Chem       Date:  1998-02       Impact factor: 8.327

5.  Use and misuse of a digoxin assay service.

Authors:  I Gibb; J C Cowan; A J Parnham; T H Thomas
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

6.  Effect of data collection method on results of serum digoxin concentration audit.

Authors:  E H Makela; S K Davis; K Piveral; W A Miller; R A Pleasants; R H Gadsden; R B Leman
Journal:  Am J Hosp Pharm       Date:  1988-01

7.  An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls.

Authors:  H W Clague; Y Twum-Barima; S G Carruthers
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

Review 8.  Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions.

Authors:  S B Soumerai; J Avorn
Journal:  Milbank Mem Fund Q Health Soc       Date:  1984

9.  Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  D W Duhme; D J Greenblatt; J Koch-Weser
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

10.  Digoxin therapeutic drug monitoring: an audit and review.

Authors:  Andrew Sidwell; Murray Barclay; Evan Begg; Grant Moore
Journal:  N Z Med J       Date:  2003-12-12
View more
  3 in total

1.  Monitoring drug therapy.

Authors:  Thierry Buclin; Verena Gotta; Aline Fuchs; Nicolas Widmer; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Appropriateness of serum digoxin levels.

Authors:  Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Giorgio Brocco; Gian Cesare Guidi
Journal:  Eur J Clin Pharmacol       Date:  2007-09-16       Impact factor: 2.953

3.  Appropriateness of digoxin measurement in hospitalized patients.

Authors:  Seyma Oncu; Ayse Gelal; Ozgur Aslan; Reyhan S Ucku
Journal:  Biochem Med (Zagreb)       Date:  2017-11-24       Impact factor: 2.313

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.